Tivdak
Tivdak ingredients
| Active ingredient | Strength |
|---|---|
| Tisotumab Vedotin | 40 mg/4mL |
What Tivdak is used for
The FDA lists the approved uses on the official label (below). In the EU, tisotumab vedotin is approved as Tivdak for:
Tivdak as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy (see section 5.1).
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Tivdak
- Generic name
- Tisotumab vedotin
- Made by
- SEAGEN INC.
- Forms
- Injection, Powder, For Solution
- Given
- Intravenous
- FDA approval
- Biologic licence (BLA) BLA761208
- On the US market since
- 2021
Official information
- MedlinePlus drug information (search for Tisotumab vedotin)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Tivdak?
Tivdak (Tisotumab vedotin) is a cancer medicine made by SEAGEN INC., approved by the US FDA.
What are the ingredients of Tivdak?
Tivdak contains Tisotumab Vedotin (40 mg/4mL).
Is Tivdak approved in Europe?
The same active substance is approved in the EU as Tivdak.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA